Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | Director | June 17, 2026 | June 22, 2026 |
| NuCana plcNCNA · Entity 8214 | Director | June 19, 2026 | June 24, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Director | June 20, 2024 | June 21, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2036-06-16 | Direct | 51,700 |
Reported balance
After 2026-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 51,700 · Balance 51,700 F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
NuCana plc
Report date June 19, 2026 · Filed June 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-19 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-19 · Disposition to issuer · Disposed 23,811,896 · Balance 0 F1: The ordinary shares, nominal value 0.000004 Pounds Sterling per share, of NuCana plc (the "Company") underlying this option were exercisable as of June 20, 2026, had an exercise price of 0.0004 Pounds Sterling per share, and were set to expire on June 20, 2035. F2: The option was canceled by mutual agreement of the Reporting Person and the Company. The Reporting Person did not receive consideration for the cancellation. |
Filing footnotes · ownership attribution and instrument terms
F1: The ordinary shares, nominal value 0.000004 Pounds Sterling per share, of NuCana plc (the "Company") underlying this option were exercisable as of June 20, 2026, had an exercise price of 0.0004 Pounds Sterling per share, and were set to expire on June 20, 2035.
F2: The option was canceled by mutual agreement of the Reporting Person and the Company. The Reporting Person did not receive consideration for the cancellation.
Omega Therapeutics, Inc.
Report date June 20, 2024 · Filed June 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2034-06-19 | Direct | 25,000 |
Reported balance
After 2024-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-20 · Grant · Acquired 25,000 · Balance 25,000 F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 19, 2026 Filed Jun 24, 2026 07:09 UTC | NuCana plc NCNA · Entity 8214 | Disposition to issuerOptions · Derivative | 23,811,896 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-280239 · ownership.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 23,811,896 shares Expires not disclosed F1 · derivative.exercise_price: The ordinary shares, nominal value 0.000004 Pounds Sterling per share, of NuCana plc (the "Company") underlying this option were exercisable as of June 20, 2026, had an exercise price of 0.0004 Pounds Sterling per share, and were set to expire on June 20, 2035. F2 · price: The option was canceled by mutual agreement of the Reporting Person and the Company. The Reporting Person did not receive consideration for the cancellation. F1 · derivative.exercise_date: The ordinary shares, nominal value 0.000004 Pounds Sterling per share, of NuCana plc (the "Company") underlying this option were exercisable as of June 20, 2026, had an exercise price of 0.0004 Pounds Sterling per share, and were set to expire on June 20, 2035. F1 · derivative.expiration_date: The ordinary shares, nominal value 0.000004 Pounds Sterling per share, of NuCana plc (the "Company") underlying this option were exercisable as of June 20, 2026, had an exercise price of 0.0004 Pounds Sterling per share, and were set to expire on June 20, 2035. Read SEC document |
| June 17, 2026 Filed Jun 22, 2026 20:28 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 51,700 | $0.00 Strike: $2.55 | $0.00 |
DisclosureSEC source: 0001650664-26-000068 · wk-form4_1782160133.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,700 Underlying: Common Stock · 51,700 shares Expires 2036-06-16 F1 · derivative.exercise_date: This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:18 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 37,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001650664-25-000101 · wk-form4_1749586723.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2035-06-05 F1 · derivative.exercise_date: This option was granted on June 6, 2025 and is scheduled to vest in full on June 6, 2026. Read SEC document |
| June 20, 2024 Filed Jun 21, 2024 20:20 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $2.20 | $0.00 |
DisclosureSEC source: 0000950170-24-076263 · ownership.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-06-19 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| May 30, 2024 Filed Jun 3, 2024 20:27 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.17 | $0.00 |
DisclosureSEC source: 0001650664-24-000058 · wk-form4_1717446440.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2034-05-29 F1 · derivative.exercise_date: This option was granted on May 30, 2024 and is scheduled to vest in full on May 30, 2025. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-23-015146 · doc4.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2033-06-06 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
| April 11, 2023 Filed Apr 13, 2023 20:53 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $6.71 | $0.00 |
DisclosureSEC source: 0001415889-23-006521 · form4-04132023_080436.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-04-10 F1 · derivative.exercise_date: This option was granted on April 11, 2023 and is scheduled to vest over three years in equal yearly installments of one-third of the shares beginning on April 11, 2024 through April 11, 2026. Read SEC document |
| June 08, 2022 Filed Jun 10, 2022 20:10 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 18,118 | $0.00 Strike: $3.31 | $0.00 |
DisclosureSEC source: 0000899243-22-021896 · doc4.xml · derivative · entry 1 Levy Elliott M. · CIK 0001858745 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,118 Underlying: Common Stock · 18,118 shares Expires 2032-06-07 F1 · derivative.exercise_date: The options vest and become exercisable on the earlier of (i) the date of the Issuer's next annual meeting of stockholders and (ii) the first anniversary of the date of grant, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.